![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 06, 2006 10:28:15 AM
Since my entry last fall in INSM I try to continually ask myself that question as the company reports on or experiences new events. We comb over each event searching for some greater or lesser meaning yet one thing continues to jump out at me...
Lazard's 12/13 upgrade: ...We arrive at our new 12-month price target of $4.00 price by applying a 5.6 enterprise value-to-revenue multiple to our new 2008 iPlex sales estimate of $119 M, discounted two years at 25%, including fully diluted shares of 109.5 million, which assumes a financing in 2006 Risks to our thesis include a delayed launch for iPlex or faster-than-anticipated launch of Increlex.
Nope, nothing's changed on the financing front. We hashed over their call for 100M fully diluted shares and eventually concluded that was going to happen by 2Q, then the company's filings confirmed it. Lazard has "called the ball".
Now, what has changed, imho?
1. the number of folks that own and/or follow INSM. It's too bad that the noise we're hearing is from those that are daytraders and absolute amateurs in biotech investing. They're pissed they got caught chasing other amateurs and they're all left to call each other names in an effort to placate their mistaken entry "strategy" and biotech experience. I do think that anyone who chased and bought, even those at $3.30 will be handsomely rewarded...if they're still around.
2. the science has been validated for Iplex w/ FDA and it's audience of medical profesionals has also increased as we are no longer excited soley about it's intended use but for applications w/ larger patient pools and for wider worldwide use.
I suggested last week this was beginning to look like an orchestrated series of corporate events and see it unfolding not as we on the outside were anticipating, guessing or pontificating BUT as an pretty well organized effort by a company executing their grand plan. I will use this as a buying opp, look forward to the next PR fm IR and am patient for INSM to exceed Lazard's tgt.
GLTA and thanks again to those that post here.
Recent INSM News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:21:15 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:23:25 PM
- Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:00:43 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:33:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:46:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:44:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:41:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 09:32:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 08:15:33 PM
- Insmed to Host Commercial Webinar on June 4, 2024 • PR Newswire (US) • 05/30/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/30/2024 08:02:27 PM
- Insmed Announces Pricing of $650 Million Public Offering of Common Stock • PR Newswire (US) • 05/30/2024 12:00:00 PM
- Insmed Announces Proposed $500 Million Public Offering of Common Stock • PR Newswire (US) • 05/28/2024 10:21:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:51:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:49:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:47:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:46:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:40:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:14:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 10:30:24 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM